

1. Company details

Name of entity:	EZZ Life Science Holdings Limited
ABN:	83 608 363 604
Reporting period:	For the year ended 30 June 2026
Previous period:	For the year ended 30 June 2025

2. Results for announcement to the market

				\$
Revenues from ordinary activities	down	36.39%	to	46,280,283
Loss from ordinary activities after tax attributable to the owners of EZZ Life Science Holdings Limited	up	179.10%	to	(5,323,589)
Loss for the year attributable to the owners of EZZ Life Science Holdings Limited	up	179.10%	to	(5,323,589)

Dividends

	Amount per security Cents	Franked amount per security Cents
Final dividend paid on 23 December 2025	2.00	2.00

Comments

Financial performance

The loss for the Group after providing for income tax amounted to \$5,323,589 (30 June 2025: profit of \$6,730,441).

The directors consider Underlying Earnings Before Interest, Tax, Depreciation and Amortisation ('EBITDA') and Underlying EBIT to reflect the core earnings of the consolidated entity. Underlying EBITDA and underlying EBIT are financial measures which are not prescribed by Australian Accounting Standards ('AAS') and represent the profit or loss under AAS adjusted for non-cash and significant items. The following table summarises key reconciling items between statutory result and the underlying results for the current and previous year:

	Consolidated 2026 \$	2025 \$
(Loss)/ Profit for the year	(5,323,589)	6,730,441
Depreciation and amortisation expense	488,411	510,858
Finance costs	17,307	27,835
Interest income	(212,517)	(417,874)
Income tax (benefit) / expense	(1,089,188)	3,855,592
Provision for expected credit losses	2,395,537	-
Share-based payments expense	2,681,630	1,903,267
Merger and acquisition project expenses	622,150	296,706
Underlying EBITDA	(420,259)	12,906,825

Financial position

The net assets decreased from \$28,085,315 as at 30 June 2025 to \$24,494,461 as at 30 June 2026.

Share capital increased from \$8,736,775 as at 30 June 2025 to \$11,399,485 as at 30 June 2026 due to the issue of shares via employee incentives schemes and the exercise of performance rights.

3. Net tangible assets

Net tangible assets per ordinary security

Reporting period Cents	Previous period Cents
51.99	59.49

The net tangible assets per ordinary security is calculated as follows:

	Consolidated 2026 \$	2025 \$
Net assets	24,494,461	28,085,315
Less: Right-of-use assets	(475,862)	(297,413)
Less: Intangibles	(28,600)	(28,130)
Add: Lease liabilities	478,592	304,489
Net tangible assets	24,468,591	28,064,261

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period

Final dividend paid on 23 December 2025

Amount per security Cents	Franked amount per security Cents
2.00	2.00

Previous period

Final dividend paid on 9 December 2024

Interim dividend paid on 17 June 2025

Amount per security Cents	Franked amount per security Cents
2.00	2.00
2.00	2.00

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

EZZ Life Science Holdings (USA) Inc., incorporated in USA.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements have been audited and an unmodified opinion has been issued.

11. Attachments

Details of attachments (if any):

The Annual Report of EZZ Life Science Holdings Limited for the year ended 30 June 2026 is attached.

12. Signed



Signed _____

Qizhou (Mark) Qin
Executive Director
Sydney

Date: 31 August 2026